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Characterization of Dopaminergic 
System in the Striatum of Young 
Adult Park2−/− Knockout Rats
Jickssa M. Gemechu1,2, Akhil Sharma1, Dongyue Yu1,3, Yuran Xie1,4, Olivia M. Merkel  1,5 & 
Anna Moszczynska  1
Mutations in parkin gene (Park2) are linked to early-onset autosomal recessive Parkinson’s disease 
(PD) and young-onset sporadic PD. Park2 knockout (PKO) rodents; however, do not display 
neurodegeneration of the nigrostriatal pathway, suggesting age-dependent compensatory changes. 
Our goal was to examine dopaminergic (DAergic) system in the striatum of 2 month-old PKO rats in 
order to characterize compensatory mechanisms that may have occurred within the system. The striata 
form wild type (WT) and PKO Long Evans male rats were assessed for the levels of DAergic markers, for 
monoamine oxidase (MAO) A and B activities and levels, and for the levels of their respective preferred 
substrates, serotonin (5-HT) and ß-phenylethylamine (ß-PEA). The PKO rats displayed lower activities 
of MAOs and higher levels of ß-PEA in the striatum than their WT counterparts. Decreased levels of 
ß-PEA receptor, trace amine-associated receptor 1 (TAAR-1), and postsynaptic DA D2 (D2L) receptor 
accompanied these alterations. Drug-naive PKO rats displayed normal locomotor activity; however, 
they displayed decreased locomotor response to a low dose of psychostimulant methamphetamine, 
suggesting altered DAergic neurotransmission in the striatum when challenged with an indirect 
agonist. Altogether, our findings suggest that 2 month-old PKO male rats have altered DAergic and 
trace aminergic signaling.
Parkin is an E3 ubiquitin-protein ligase with neuroprotective properties. The main function of parkin is associated 
with the ubiquitin-proteasome system, a predominant cellular pathway responsible for targeting specific proteins 
for degradation. Parkin has also other functions e.g., regulation of trafficking of membrane proteins, including 
dopamine transporter (DAT), maintenance of mitochondrial homeostasis, and axonal transport1. Mutations in 
parkin gene (Park2) account for 50% of familial Parkinson’s disease (PD) cases, causing autosomal recessive juve-
nile PD, and for approximately 20% of young onset sporadic PD2,3. Oxidative stress and aggregation-mediated 
parkin loss of function is also linked to sporadic PD4,5. Conversely, overexpression of parkin protects dopamine 
(DA) neurons in animal models of the disease6,7, suggesting the importance of parkin in DA neuron function and 
maintenance.
Despite intensive research, the exact role of parkin deficit in development of PD is still unclear. Majority of 
parkin knockout (PKO) mouse models, or recently generated PKO rats, do not display PD-like motor impair-
ments or any indication of progressive degeneration of nigrostriatal DA pathway8,9. Some of parkin mutation 
models, conditional parkin knockout, and combination of parkin gene knockout with a knockout of other gene 
were able to recapitulate major features of PD8,10. In majority of the aforementioned studies, PKO rodents were 
examined for nigrostriatal pathway degeneration at the later stages of life. The failure of older animals to develop 
PD could have been caused by compensatory mechanisms in the brain11–14. Younger PKO rodents may, at least in 
part, mimic pre-symptomatic stages of PD15,16. The studies in PKO mice suggest that loss of parkin protein may 
result in decreased release of presynaptic DA (reviewed in8,10).
The major objective of the present study was to characterize the DAergic system in the striatum of young 
adult (2 month-old) PKO rats in order to characterize compensatory mechanisms that may have occurred in the 
striatum lacking parkin as well as to elucidate potential early signs of PD in these rats. We measured the levels 
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of DA and its metabolites, the levels of DA synthesizing enzyme tyrosine hydroxylase (TH), the levels of dopa-
mine transporter (DAT), vesicular monoamine transporter 2 (VMAT2), and DA D2 receptor isoforms (D2S and 
D2L) in the striatum of male PKO and WT Long Evans rats. In addition, we assessed the activities and levels of 
DA metabolizing enzymes, monoamine oxidase A and B (MAO-A and MAO-B), and the levels of MAO-A and 
MAO-B preferred substrates, serotonin (5-HT) and ß-phenylethylamine (ß-PEA), respectively. Of relevance to 
the objective of this study, 5-HT and ß-PEA are known regulators DAergic neurotransmission17,18. We have also 
examined the expression of genes coding for proteins with altered levels. Finally, we assessed basal motor activity 
and locomotor response to a low dose of a psychostimulant methamphetamine in the PKO vs. WT rats.
The 2 month-old PKO rats displayed no signs DAergic neurotoxicity (i.e. deficits in DAergic markers) in 
the striatum. However, several alterations relevant to DAergic neurotransmission were detected. The activity of 
MAO-A and particularly the activity of MAO-B were significantly decreased. Despite these decreases, there was 
no indication of the presence of DA-mediated oxidative stress in the striatum of these rats as assessed by lack 
of an increase in the levels of DA quinones or lipid peroxidation by-product, 2-hydroxynonenal (4-HNE). The 
decreased activity of MAO-B was accompanied by significantly increased levels of MAO-B preferred substrate 
ß-PEA and decreased levels of trace amine-associated receptor 1 (TAAR-1), a receptor for ß-PEA. We also found 
decreased levels of striatal postsynaptic DA D2L receptor in the knockouts. The expression of DRD2 gene was 
increased while the expression of MAOB and TAAR1 genes was unaltered which led us to examine transactiva-
tion DNA-binding protein (TDP-43), a DNA/RNA-binding protein involved in regulation of transcription and 
translation processes, and a substrate of parkin. We found a decrease in the levels of TDP-43 protein. The basal 
locomotor activity was not significantly different between the genotypes, while rapid stereotypic movements were 
significantly but slightly decreased in the PKO rats. The locomotor response to methamphetamine was decreased 
in the knockouts compared to the WT controls.
Collectively, our results indicate that loss of parkin protein does not result in development of significant 
DAergic deficits or motor abnormalities in 2 month-old PKO rats; however, it leads to some alterations in 
DAergic and trace aminergic signaling aimed to balance the behavioral outcome. Environmental insults, such as 
methamphetamine abuse, might destroy this compensatory equilibrium and lead to development of Parkinsonian 
features. Our results strengthen the idea that species differences might have implications for the individualized 
treatment of PD.
Results
Validation of Park2 gene knockout. The loss of parkin protein in the homozygous PKO rats was 
ascertained using SDS-PAGE and western blot analysis (with two different parkin antibodies) as described in 
the Materials and Methods section. The analysis demonstrated a complete loss of parkin protein in PKO rats 
(Fig. 1A).
The effect of parkin deficit on body weight and core body temperature. In contrast to Park2−/− 
knockout mice11,19,20, the Park2−/− knockout rats displayed normal core body temperature (Fig. 1B) and higher 
body weight between the ages of 1 and 2 months than the age-matched WT controls (+12.6%, Student’s t-test, 
p < 0.001, n = 12) (Fig. 1C).
The effect of parkin deficit on cytoskeletal protein levels. Both α-tubulin and ß-tubulin are sub-
strates of parkin21. Actins were not demonstrated to be substrates of parkin22 but parkin is known to interact with 
actin filaments23. To assess whether the loss of parkin protein affects α-tubulin and ß-actin protein levels, whole 
synaptosomes and synaptosomal fractions were prepared from the striata of 2 month-old PKO and WT rats and 
quantitatively analyzed in relation to total protein levels (estimated by Ponceau S staining). We found similar 
levels of α-tubulin as well as ß-actin in lysates as well as in whole synaptosomes from the PKO and WT rats. 
In contrast, ß-actin immunoreactivity in synaptosomal fractions differed between the two groups. In the PKO 
group, ß-actin immunoreactivity was higher in the membrane-endosomal fraction (+20%, p < 0.05, Student’s 
t-test, n = 4) and lower in the cytosol-vesicular fraction (−16%, p > 0.1, Student’s t-test, n = 4). Similar trends 
were detected for immunoreactivity of α-tubulin; however, the changes did not reached statistical significance 
(not shown). Since neither ß-actin nor α-tubulin proved to be a reliable gel loading control in the experiments 
employing striatal synaptosomal fractions; total protein content (Ponceau S staining) was used as a loading con-
trol in experiments involving the fractions. ß-Actin was used as a loading control when total synaptosomal frac-
tions or whole tissue lysates were assessed.
The effect of parkin deficit on synthesis, storage, and metabolism of striatal dopamine. Whole 
synaptosomes and synaptosomal fractions were prepared from the striata of 2 month-old PKO and WT 
rats and assessed for the levels of TH, a rate-limiting enzyme in DA synthesis and for the levels of VMAT2, 
a vesicular transporter packaging DA to the storage vesicles. The striatal content of DA and its metabolites, 
3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), and (3-methoxytyramine (3-MT) was 
assessed in striatal lysates. We found no significant difference in the immunoreactivity of TH, detected at ~60 kDa, 
between the PKO rats and their WT counterparts (Fig. 2A). The immunoreactivity of VMAT2 was detected at 
~70–75 kDa and 55 kDa, representing glycosylated and partially glycosylated form of VMAT2, respectively. This 
pattern of VMAT2 reactivity has been reported in the rat24,25 and human26,27 brain. The loss of parkin protein did 
not affect total VMAT2 levels (calculated as sum of all bands) or subcellular distribution of VMAT2 (Fig. 2B). 
Figure 2B(i) shows a representative blot containing all fractions together on the same blot and the correspond-
ing total protein content. Figure 2B(ii) shows total levels of VMAT2 and corresponding ß-actin levels as well 
as another representative blot showing VMAT2 levels in synaptosomal fractions. Of note, a ~65 kDa band was 
observed in the vesicular fraction instead of the 75–80 kDa band, probably representing another glycosylated 
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species of the VMAT2. No statistically significant differences were found in the levels of DA and its metabolites in 
the PKO rats compared to the WT controls (Table 1). To assess metabolism of intracellular DA, the DOPAC/DA 
ratios were calculated and found not to differ significantly between the genotypes (Table 1). To assess metabolism 
of extracellular DA, the 3-MT/DA and 3-MT/DOPAC ratios were calculated. Both ratios were similar in the PKO 
group and the WT group (Table 1), suggesting unaltered DA release and metabolism outside DAergic terminals. 
Overall, the data suggested normal DA synthesis, storage, and metabolism in the striatum of 2 month-old PKO 
rats.
Loss of parkin protein decreases the activity of monoamine oxidase B in the rat striatum. To 
further characterize the effect of Park2 knockout on DA metabolism, we measured activities of MAO-A and 
MAO-B in mitochondria isolated from the striata of PKO and WT rats, monitoring the rate of H2O2 produc-
tion over 30 min (Fig. 3A, graph on the right). In rat brain, MAO-A is a major isoform metabolizing DA with 
MAO-B being minimally involved in DA metabolism, preferentially metabolizing ß-PEA28–32. Striatal activities 
of both monoamine oxidases, particularly of MAO-B, were significantly reduced (−27% and −46%, respectively, 
p < 0.05, Student’s t-test, n = 6) in the PKO rats compared to the WT controls (Fig. 3A, graph on the left). This 
result was unexpected as available literature data reports increased levels, or activities, of MAO-A and MAO-B 
upon parkin gene knockout33,34. The assessment of MAO-B protein levels in the striatum (by calculation of immu-
noreactivity of the ~58 kDa band) revealed no difference in MAO-B protein levels between the knockouts and the 
controls (Fig. 3B) .
The decreased activity of MAO-A introduced a possibility of increased levels of cytoplasmic DA and 
DA-mediated oxidative stress in the striatum of PKO rats. To investigate this possibility, the levels of DA quinones 
and 4-HNE, a by-product of lipid peroxidation, were assessed in the striata. There was no detectable immunore-
activity for DA quinone-modified proteins in striatal synaptosomes or lysates from the WT or PKO rats (Fig. 3C). 
The immunoreactivity for 4-HNE-conjugated proteins in striatal synaptosomes was also no different in the PKO 
rats than in the WT controls (not shown).
Loss of parkin protein alters the levels of ß-phenylethylamine and trace amine-associated 
receptor 1 in the rat striatum. While ß-PEA is a preferred substrate for MAO-B in rat brain31,32, 5-HT 
is a preferred substrate for MAO-A29. The levels of 5-HT, its metabolite 5-hydroxyindoleacetic acid (5-HIAA), 
and 5-HIAA/5-HT ratio did not significantly differ from the control values (5-HT: 6.16 ± 0.47 vs. 5.19 ± 1.27 pg/
µg protein; 5-HIAA: 4.60 ± 0.32 vs. 4.16 ± 0.58 pg/µg protein; 5-HIAA/5-HT: 0.757 ± 0.028 vs. 0.963 ± 0.170, in 
PKO vs. WT rats). The ß-PEA data was highly variable, most likely due to the fact that ß-PEA levels are low in 
Figure 1. Validation of Park2 gene knockout and the effects of parkin deficit on core body temperature 
and body weight. (A) Homozygous parkin knockout (PKO) and wild type (WT) Long Evans male rats were 
sacrificed at the age of 2 months. The striata were dissected out and analyzed for parkin immunoreactivity using 
SDS-PAGE and western blot analysis with two different anti-parkin antibodies. The analysis demonstrated a 
complete loss of parkin immunoreactivity in the PKO rats (n = 6). (B) Core body temperatures and body weight 
was assessed in the WT and PKO rats. The PKO rats displayed normal core body temperature (B) and higher 
body weight than the age-matched WT controls (+12.6%, Student’s t-test, p < 0.001, n = 12) (C). The data are 
expressed as mean ± SEM. ***p < 0.001. Abbreviations: PKO, parkin knockout; WT, wild type.
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the brain and, therefore, difficult to assess with precision (Fig. 4A). The levels of ß-PEA were significantly higher 
in striata from the PKO rats compared to the WT rats (+33%, PKO: 0.107 ± 0.008 vs. WT: 0.081 ± 0.008 pmol/
mg protein, p < 0.05, n = 6) (Fig. 4B). ß-PEA levels in the DA-poor cerebellum (assessed to determine whether 
the changes in ß-PEA are specific to the DA-rich striatum) were not significantly different between the genotypes 
(PKO: 0.036 ± 0.006 vs. WT: 0.031 ± 0.006 pmol/mg protein, n = 6) (Fig. 4C). The ß-PEA data was analyzed 
Figure 2. The effect of parkin protein loss on synthesis and storage of striatal dopamine. Whole synaptosomes 
and synaptosomal fractions were isolated from striata of the 2 month-old parkin knockout (PKO) and wild 
type (WT) Long Evans male rats. Compared with the WT controls, there was no significant difference in 
the immunoreactivity of (A) TH (detected at ~60 kDa) or (B) VMAT2 (detected at ~70–75 kDa and 55 kDa, 
representing glycosylated and partially glycosylated VMAT2, respectively) in synaptosomal fractions from 
the striata of WT and PKO rats. An additional band of ~65 kDa was apparent in the vesicular fraction of 
VMAT2. (2Bi) A representative blot containing all synaptosomal fractions and the corresponding total 
protein content. (2Bii) VMAT2 levels in total synaptosomal fraction and corresponding ß-actin levels as well 
as another representative blot showing VMAT2 in synaptosomal fractions. Abbreviations: Mem, membrane 
fraction; Ves, vesicular fraction; VMAT2, vesicular monoamine transporter 2; TH, tyrosine hydroxylase; Tot, 
total synaptosomal fraction. The data are expressed as mean ± SEM.
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5SCIentIfIC RepoRtS |  (2018) 8:1517  | DOI:10.1038/s41598-017-18526-0
by two-way ANOVA followed by Holm-Sidak’s post hoc test. There was a significant effect of genotype (F(1, 
20) = 5.11, p < 0.05) and a significant effect of brain area (F(1, 20) = 74.9, p < 0.0001).
The TAAR-1 receptor is a member of recently identified TAAR family of G protein-coupled receptors35 and a 
receptor for trace amines such as ß-PEA as well as a receptor for amphetamines36. TAAR-1 localizes intracellularly 
in presynaptic and postsynaptic neuronal elements37. Disease states associated with impaired TAAR-1 function 
include drug abuse, obesity, diabetes, schizophrenia, and PD38–40. We next assessed whether the increase in ß-PEA 
levels affected protein levels of TAAR-1 in striatal and cerebellar lysates from the PKO rats. First, we validated 
the anti-TAAR-1 antibody. As shown in Fig. 5Aa, no signal for TAAR-1 receptor was observed in striatal slices 
from TAAR1−/− knockout rats. Immunochemical staining of striatal slices from the WT and PKO rats with the 
TAAR-1 antibody revealed diffuse cytoplasmic signal (Fig. 5Ac), which was decreased in the knockouts com-
pared to the controls (−33%, Student’s t-test, p < 0.01, n = 3) (Fig. 5Ae). Subsequently, the same antibody was 
used in SDS-PAGE/western blotting to confirm the decrease in TAAR-1 receptor levels. The expected molecular 
weight for the TAAR-1 is ~39 kDa. This bare form of the receptor is usually observed at 34–39 kDa and its gly-
cosylated form is observed at 43–52 kDa. In our hands, the TAAR-1 immunoreactivity was detected at ~43 kDa 
and ~56 kDa band, with the latter most likely reflecting glycosylated form of the receptor41. To determine whether 
parkin deficit differentially affects TAAR-1 in different brain areas, the levels of TAAR-1 were assessed in DA-rich 
striatum and DA-poor cerebellum in the PKO and the WT rats. Two-way ANOVA revealed a significant effect 
of brain area (F(1, 26) = 5.77, p < 0.05) but not of genotype (F(1, 26) = 4.17, p = 0.051). However, there was a 
significant area x genotype interaction (F(1, 26) = 5.77, p < 0.05), indicating a difference between genotypes in 
the striatum but not in the cerebellum. The immunoreactivity of the 56-kDa band was significantly decreased 
(−36%, p < 0.01, two-way ANOVA followed by Holm-Sidak’s post hoc test, n = 9) in the striatum of the PKO rats 
compared to the WT rats (Fig. 5B). The immunoreactivity of 56 kDa TAAR-1 band in the cerebellum of the PKO 
rats did not show a decrease (Fig. 5C). In the PKO rats, the immunoreactivity of unglycosylated TAAR-1 was no 
different from the control values (Fig. 5B,C). In addition to 43 kDa and 56 kDa bands, the anti-TAAR-1 antibody 
detected bands above 72 kDa in both PKO and WT samples. These bands are most likely non-specific bands.
Loss of parkin protein decreases the levels of postsynaptic dopamine D2 receptor in the rat 
striatum. The TAAR-1 receptor is known to modulate presynaptic and postsynaptic DA D2 receptors while 
ß-PEA was reported to modulate postsynaptic D2 receptor (D2L)42–44. Therefore, we next evaluated the total 
levels of DA D2 receptor (D2(S + L)), and the levels of its postsynaptic isoform, i.e. D2L receptor, in the striatal 
lysates from the WT and PKO rats. As previously reported by us25, the antibody against D2L receptor detected 
partially glycosylated D2L receptor (~55 kDa) whereas the antibody against presynaptic and postsynaptic D2 
receptor (D2(S + L)) recognized D2 receptor at different states of glycosylation (50, 72 and ~80–100 kDa). Both 
antibodies have previously been used in other studies (e.g.45–47). Compared to the WT controls, the levels of D2L 
receptor were significantly decreased in striatal lysates from the PKO rats (−27%, p < 0.01, Student’s t-test, n = 7) 
(Fig. 6A) whereas the total levels of D2 receptor (S + L) where not significantly changed (not shown). These 
results suggest that the levels of presynaptic D2 receptor (D2S) may be increased in the striatum of the PKO rats.
The DAT is a plasma membrane transporter responsible for uptake of DA back into DAergic terminals. The 
levels of DAT were assessed to estimate DA uptake. The antibody against the DAT detected fully glycosylated 
form of the transporter (~70 kDa)25. The immunoreactivity of striatal DAT was not significantly different than the 
control levels of the transporter in most of the PKO rats (Fig. 6B).
The effects of parkin deficit on the expression of TAAR1, DRD2, and MAOB gene. To determine 
whether the decreases in TAAR-1 and D2L levels were due to decreases in their gene expression, we employed the 
qPCR. The data was analyzed by delta CT method and normalized to WT controls. Two-way ANOVA revealed 
a significant effect of genotype (F(1, 50) = 4.88, p < 0.05) as well as gene (F(3, 50) = 343, p < 0.0001) and signifi-
cant genotype x gene interaction (F(3, 50) = 2.87, p < 0.05). In contrast to our expectations, the levels of TAAR1 
mRNA did not significantly differ from the control values whereas the levels of DRD2 mRNA were significantly 
increased (+18%, p < 0.05, two-way ANOVA followed by Holm-Sidak’s post hoc test, n = 6–9) (Fig. 7). The ace-
tylcholine receptor subunit alpha-7 (CHRNA7) gene expression served as a non-DAergic gene control.
Loss of parkin protein decreases protein-protein interactions of TDP-43 protein. Altered levels 
of TAAR-1, D2L, or MAO-B without similar alterations in their gene expression suggested that parkin deficiency 
might affect the process of translation. To determine whether the loss of parkin affects mRNA-protein translation 
WT PKO
DA 111 ± 6 109 ± 14
DOPAC 13.4 ± 1.0 15.1 ± 1.7
HVA 2.68 ± 0.19 2.69 ± 0.10
3-MT 0.993 ± 0.090 0.935 ± 0.209
DOPAC/DA 0.104 ± 0.007 0.105 ± 0.009
3-MT/DA 0.009 ± 0.012 0.012 ± 0.018
3-MT/DOPAC 0.079 ± 0.02 0.079 ± 0.017
Table 1. Dopamine (DA), DA metabolites and DA metabolism in wild type (WT) and parkin knockout (PKO) 
2 month-old rats. Values are expressed as mean ± SEM in pg/µg protein.
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in the striatum of PKO rats, we assessed the levels of transactivation DNA-binding protein (TDP-43), a DNA/
RNA-binding protein involved in regulation of transcription and translation processes48,49. TDP-43 is ubiquiti-
nated by parkin50 and its levels are increased in parkin knockout mice51. The anti-TDP-43 antibody was validated 
Figure 3. The effect of parkin protein loss on striatal dopamine metabolism. (A,B) Mitochondria isolated 
from the striata of parkin knockout (PKO) and wild type (WT) rats, monitoring the rate of H2O2 production 
over 30 min (Fig. 3A, graph on the right). (A) In the PKO rats, striatal activity of MAO-A and MAO-B 
was significantly reduced (−27% and −46%, respectively, p < 0.05, Student’s t-test, n = 6) compared to the 
WT controls. MAO-B activity, measured with p-tyramine as a substrate for both isoforms, was linear over 
measured 30 min time period. (B) SDS-PAGE and western blotting analysis revealed no difference in the levels 
of MAO-B protein (n = 6) . (C) Lack of immunoreactivity for proteins modified by DA quinones in the striatal 
lysates of WT and PKO rats; DA quinone-modified bovine serum albumin serves as a positive control. The data 
are expresses as mean ± SEM. *p < 0.05. Abbreviations: BSA, bovine serum albumin; DA, dopamine; DAQ, 
dopamine quinone; MAO, monoamine oxidase.
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in PC12 cells and TDP-43 was found, as expected, in the nucleus (Fig. 8A). We detected two main bands, ~52 kDa 
and ~70 kDa band (Fig. 8B). Neither of these bands represented TDP-43-RNA or TDP-43-DNA complex as 
treatment of the samples with benzonase nuclease did not result in a single 43 kDa band (not shown). Similar 
bands were observed in other studies employing WT samples50,52,53. The 52 kDa band is likely ubiquitinated 
TDP-4353 while the 70 kDa band may be a complex of TDP-43 with one of its interacting protein partners. In 
addition to the weak ~43 kDa band, a weak, likely non-specific, band of ~26 kDa was also observed on the mem-
branes (Fig. 8B). Two-way ANOVA revealed a main effect of genotype (F(1, 38) = 9.24, p < 0.01) (Fig. 8C). The 
43 kDa and 52 kDa bands did not differ in optical density between the PKO and WT rats while 70 kDa band was 
of lower density in the PKO rats compared to the controls (−37%, p < 0.01, two-way ANOVA with Holm-Sidak’s 
post hoc test, n = 6–9) (Fig. 8C). The total intensity of the three bands was slightly decreased in the striatum 
of PKO rats compared to WT controls (WT: 1.00 ± 0.10 vs. PKO: 0.76 ± 0.06; −24%, p < 0.05, Student’s t-test).
Loss of parkin protein decreases locomotor response to methamphetamine challenge. Next, 
we tested whether the observed alterations in DAergic and trace aminergic system affected motor activity in PKO 
rats. Small stereotypic movements (including grooming) measured within 30 min time frame were significantly 
decreased in the PKO rats compared to the controls (−18%, Student’s t-test p < 0.05, n = 6) (Fig. 9A). There was 
no difference between the PKO and WT rats in distance traveled over 30 min timeframe (Fig. 9B). However, the 
locomotor response of PKO to 2 mg/kg injection methamphetamine was significantly lower than the response of 
WT controls (−39%, Student’s t-test, n = 6) (Fig. 9C).
Discussion
Parkin is a neuroprotective ubiquitin protein ligase with multiple substrates and functions, which contributes to 
development of PD54,55. Surprisingly, neither PKO mice (between 3 and 24 months of age)8 nor PKO rats (between 
4 and 8 months of age) display nigrostriatal system degeneration9. The present study aimed to characterize 
DAergic system in the striatum of 2 month-old PKO Long Evans male rats and demonstrated that homogenous 
Figure 4. The effect of parkin protein loss on the striatal levels of ß-phenylethylamine. Tissue lysates were 
prepared from striata of the 2 month-old parkin knockout (PKO) and wild type (WT) Long Evans male rats. 
(A) A representative peak of ß-phenylethylamine (ß-PEA) and the standard curve. (B,C) The levels of ß-PEA 
were significantly higher in the striatum (+33%, p < 0.05, n = 6) (B) but not in the cerebellum (p > 0.1, n = 6) 
(C) in the PKO rats as compared to the WT rats. The data are expressed as mean ± SEM. *p < 0.05, two-way 
ANOVA with Holm-Sidak’s post hoc test.
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knockout of Park2 gene (exon 4) and loss of parkin protein were associated with an increase in striatal levels of 
ß-PEA and deficits in MAO-B/A, D2L receptor and TAAR-1 receptor in the striatum. The changes were not asso-
ciated with deficits in presynaptic DAergic markers nor were they associated with significant motor impairments. 
They were associated with a decrease in methamphetamine-evoked DA release.
Figure 5. The effect of parkin protein loss on the striatal levels of trace amine-associated receptor 1. (A) Tissue 
lysates were prepared from striata of the 2 month-old parkin knockout (PKO) and wild type (WT) Long Evans 
male rats. (a) Validation of antibody against trace amine-associated receptor 1 (TAAR-1). There was no signal 
for TAAR-1 receptor in striatal slices from TAAR1−/− knockout rats. (b, c) Immunochemical staining of striatal 
slices from the WT rats and the PKO rats with the TAAR-1 antibody revealed diffuse cytoplasmic signal. (d) 
The no-primary antibody negative control for TAAR-1 antibody. (e) Quantification of TAAR-1 immunostaining 
revealed decreased levels of the receptor in the PKO rats compared to the WT controls (−33%, Student’s t-test, 
p < 0.01, n = 3). (B) Assessment of TAAR-1 levels in striatal lysates by SDS-PAGE and western blotting. The 
immunoreactivity of the 56 kDa band (glycosylated TAAR-1) was significantly decreased (−36%, p < 0.01, 
two-way ANOVA followed by Holm-Sidak’s post hoc test, n = 9) in the striatum of PKO rats compared to the 
WT controls. (C) The immunoreactivity of 56 kDa TAAR-1 band in the cerebellum of PKO rats did not show a 
decrease. The data are expresses as mean ± SEM, **p < 0.001.
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Three exon 3-deleted PKO mouse lines (20 days to 12 months of age) displayed significantly reduced body 
weight11,19,20,56 that was concomitant with decreased body temperature in one of these studies19. In addition, the 
average body weight of PKO mice with a mixed C57BL6/129S4 background described by Perez and Palmiter 
was decreased compared to controls at 6 months of age but not younger or older57. However, this was not the 
case for mice with a 129S4 genetic background generated by the same group. The 2 month-old exon 4-deleted 
male Long Evans rats used in our study displayed unaltered core body temperature and increased body weight, 
supporting the existing evidence for age, genetic background, and exon-mediated differences in PKO rodents. 
Importantly, our findings add to this knowledge the existence of species differences. Exon 3-deleted 3 month-old 
C57BL6/129S4 PKO mice fed food rich in fat and cholesterol resisted weight gain via altered fat uptake and lipid 
metabolism56. It is possible that the young adult PKO rats have different fat uptake and/or lipid metabolism than 
the young adult PKO mice or that these processes do not largely depend on parkin function in rats as they do in 
mice. Alternatively, high body weight in PKO rats is related to decreased levels of TDP-43 protein in the brain and 
liver. TDP-43 regulates the expression and protein levels of parkin49,50,58. Conversely, parkin is known to regulate 
TDP-43 function50,51. TDP-43 mutant knock-in mice display a loss of body weight compared to WT controls59, 
suggesting that TDP-43 knockout or knockdown would result in a weight gain. Along different lines, TAAR1 
activation has been shown to prevent olanzapine-induced weight gain38; therefore, a decrease in TAAR-1 protein 
levels in PKO rats may contribute to higher than normal body weight in these rats.
In agreement with previous studies that did not find significant changes in the levels of α-tubulin, a substrate 
of parkin, in striata of PKO mice60,61, we found no changes in α-tubulin levels in striatal synaptosomes from the 
PKO rats compared to the WT controls. Parkin was reported to interact with actin filaments23; therefore, the 
increased levels of ß-actin in the endosomal-membrane fraction may reflect a compensatory increase in ß-actin 
interacting with the plasma membrane.
Neurochemical quantification of striatal tissue from young adult (3 month-old) PKO mice reported nor-
mal levels of DA and contradictory results on the levels of DOPAC and HVA in the striatum. Thus, increased 
DOPAC and/or HVA levels were reported in two studies62,63 with no change reported in one study11. Our find-
ing of unchanged levels of DA, DOPAC and HVA agrees with the latter report in mice and with a study on 4–8 
month-old PKO rats that also found no alterations in the same DAergic markers9. The ratio DOPAC/DA and 
Figure 6. The effect of parkin protein loss on the levels of postsynaptic dopamine D2 receptor and dopamine 
transporter in the rat striatum. Tissue lysates were prepared form striata of the 2 month-old parkin knockout 
(PKO) and wild type (WT) Long Evans male rats. (A) The levels of postsynaptic D2 receptor (D2L) (~55 kDa) 
were significantly decreased (−27%, p < 0.01, Student’s t-test, n = 7–9) in the striatum of PKO rats compared to 
the striatum of WT controls. (B) The immunoreactivity of glycosylated dopamine transporter (DAT) (detected 
at ~70 kDa) did not significantly differ between the PKO and WT phenotypes in the majority of the PKO rats  
(n = 15–17). The data are expressed as mean ± SEM, **p < 0.01.
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3-MT/DA are considered to reflect intracellular vs. extracellular DA metabolism (or stored and released DA), 
respectively. Our finding of unaltered content of striatal DA and unaltered DA intracellular metabolism (mani-
fested by unaltered DOPAC/DA ratio) suggest normal DA synthesis, storage and uptake in the absence of parkin 
protein. In agreement with this conclusion, we found no difference in the levels of TH, a rate-limiting enzyme in 
DA synthesis, in the levels of DAT, a transporter responsible for DA uptake back to the terminal, or in the levels of 
VMAT2, an antiporter packaging DA to the storage vesicles, between the PKO and the WT rats. Our TH results 
agree with those obtained by other laboratories9,11,19,63. Regarding the VMAT2, one of the previous studies found 
a decrease while another study found no change in striatal VMAT2 levels in old mice (11 month-old and 12 
month-old mice, respectively)19,64. Of note, we did not measure the rate of DA uptake by the VMAT2 neither did 
we measure DA content in DA storage vesicles. Therefore, as suggested by a study in PKO mice19, it is possible that 
PKO rats have different sizes of stored and cytosolic DA pools than their WT counterparts.
Lack of an increase in DA levels in view of decreased MAO-A activity could be explained by the fact that 
MAO-A activity was measured under the Vmax conditions and, therefore, reflects the levels rather than the func-
tion of the enzyme. The concentration of DA in the cytoplasm is below the Km value, i.e. affinity of MAO-A for 
DA. Consequently, intracellular DA metabolism could have increased regardless of the decrease in the levels of 
MAO-A. Alternatively or in addition, DA synthesis could have decreased due to decreased TH affinity for DA, 
without changes in TH levels. The third possibility is a smaller than normal cytoplasmic pool of DA in PKO 
rats accompanied by a larger vesicular DA pool. This scenario is supported by lower locomotor response of the 
PKO rats than the response of the WT rats to 2 mg/kg methamphetamine. Methamphetamine dose dependently 
releases cytoplasmic DA and, at higher doses, vesicular DA through the reversed DAT.
Studies in young PKO mice reported normal DAT function62,63,65, increased extracellular DA levels62 and a 
reduction11,65 or no change15,66 in electrical stimulation-evoked release of DA. An explanation for these seemingly 
contradictory results was offered by the results from the study of Rial and colleagues15: a leakage of DA via the 
DAT, independent of vesicular release of DA and of DA uptake. Compared to the WT controls, we found unal-
tered 3-MT/DA and 3-MT/DOPAC ratios in the striatum of parkin knockouts, suggesting that extracellular levels 
of DA and its metabolism do not differ between the WT and PKO rats. In agreement with this conclusion and 
with a previous study in 3 month-old male mice63, we found unchanged levels of the DAT, a transporter respon-
sible for the rapid reuptake of released DA67, in majority of our PKO rats.
Collectively, the data suggests normal DA synthesis, metabolism, release, and uptake, with potentially higher 
DA content in the storage vesicles and lower DA cytoplasmic pool in PKO rats. The discrepancy in the results 
Figure 7. The effects of parkin deficit on the expression of TAAR1, DRD2, or MAOB gene. (A) The mRNA 
was isolated from the striata of 2 month-old parkin knockout (PKO) and wild type (WT) rats and assessed for 
quality. (B) Real-time Polymerase Chain Reaction (qPCR) analysis showed that the levels of TAAR1 and MAOB 
mRNA did not significantly differ form the control values whereas the levels of DRD2 mRNA were significantly 
increased (+18%, p < 0.05, two-way ANOVA followed by Holm-Sidak’s post hoc test, n = 6–9). The levels of 
“control” CHRNA7 gene were also at the control values. The data are expressed as mean ± SEM, *p < 0.05. 
Abbreviations: CHRNA7, acetylcholine receptor subunit; D2R2, dopamine D2 receptor; alpha-7; MAOB, 
monoamine oxidase B; TAAR1, trace amine-associated receptor 1.
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from different laboratories might be explained by strain and species differences, differences in generating parkin 
knockouts (targeting exon 2, 3, or 7 in mice and exon 4 in rats) as well as by different ages of laboratory animals.
ß-PEA behaves as amphetamines and can reverse the DAT, resulting in DA release68,69. However, the available 
data indicates that the levels of ß-PEA have to increase several fold for this process to occur37. The finding of only 
32% increase in this trace amine levels together with the data discussed above indicate a lack of DA leakage via the 
DAT and also a lack of DA uptake inhibition due to competition of ß-PEA for the binding to the transporter. Of 
note, the DA-depleting effect of ß-PEA on the VMAT268 could explain previously reported reduction in quantal 
size of evoked DA release in 2–3 month-old PKO mice65, if indeed these mice have increased ß-PEA levels. A 
potential ß-PEA-induced leakage of DA from the DA storage vesicles could increase formation of toxic products 
of DA oxidation. We did not detect DA quinones or 4-HNE-protein adducts in the striata of PKO rats. These 
species were either disposed of by upregulated antioxidant machinery in the PKO rats, including reduced glu-
tathione60,61,63, or the hypothesized DA leakage does not take place in the PKO rats. As noted previously, the PKO 
rats may have a decreased pool of cytoplasmic DA and an increased pool of stored DA compared to WT animals.
In human brain, MAO-B metabolizes ß-PEA and to a high degree DA70. In rat brain, MAO-B preferen-
tially metabolizes ß-PEA, while DA is metabolized to a much greater extent, by MAO-A28–32. DAergic termi-
nals contain MAO-A while astrocytes contain both MAO-A and MAO-B71–73. Our finding of decreased MAO-B 
activity in striatal mitochondria from the PKO rats indicated functional deficit in this enzyme and reduction in 
Figure 8. The effect of parkin protein loss on the levels of transactivation DNA-binding protein (TDP-43). 
(A) The anti-TDP-43 antibody was validated in PC12 cells and found, as expected, in the nucleus. (B) The 
immunoreactivity of TDP-43 was detected as 43 kDa band and two other bands, ~52 kDa and ~70 kDa band. 
A weak, potentially non-specific band of ~26 KDa was also observed on the membranes. (C) The 43 kDa and 
52 kDa bands did not differ in optical density between the PKO and WT rats while 70 kDa band showed a trend 
for lower density in the PKO rats compared to the controls (−37%, p < 0.1, two-way ANOVA with Holm-Sidak’s 
post hoc test, n = 6–9). The data are expressed as mean ± SEM).
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metabolism of ß-PEA in striatal astrocytes. We hypothesized that parkin deficit decreased MAOB gene expres-
sion. The expression of MAOB gene is regulated by peroxisome proliferator-activated receptor gamma coactivator 
1-alpha (PGC-1α)74. PGC-1α is downregulated by increased levels of PARIS, which is a substrate of parkin; con-
sequently, PARIS content increases in response to parkin protein loss12. The decrease in MAO-B activity; however, 
was not accompanied by decreased expression of MAOB gene in the knockouts. Moreover, using SDS-PAGE 
and western blotting, we found MAO-B protein levels to be unchanged. Our findings are not in agreement with 
previous findings. Thus, MAO-B expression was increased in B lymphocyte cell line from male PD patients with 
homozygous deletion of parkin exon 433, while MAO-B activity was increased in whole brain preparations from 
1 month-old male mice with homogenous deletion of parkin exon 334 and in the substantia nigra pars compacta 
of PD patients75. Conversely, MAO-B (and MAO-A) expression and activity was decreased in cultured DAergic 
neuroblastoma SH-5YSY cells and non-DAergic cell lines upon overexpression of parkin33,76. Of note, MAO-B 
activity was unchanged in the striatum in female 14 month-old mice with homogenous deletion of parkin exon 
360. Our finding of unchanged MAO-B levels, accompanied by the decreased Vmax in parkin knockouts may reflect 
noncompetitive or uncompetitive inhibition, altered conformation, or different splice variant of MAO-B enzyme 
with different kinetic characteristics than the one observed in WT rats.
Figure 9. The effect of parkin protein loss on motor behaviors. The parkin knockout (PKO) and wild type 
(WT) Long Evans male rats were assessed for locomotor activity, stereotypic movements at the response to 
2 mg/kg methamphetamine at the age of 2 months. (A) Compared to the WT controls, the PKO rats showed 
a significantly decreased stereotypic movements (−18%, p < 0.05, Student’s t-test, n = 6). (B) There was no 
difference between PKO and WT rats in distance traveled over 30 min. (C) The locomotor response of PKO to 
2 mg/kg dose of methamphetamine (METH) was significantly lower than the response of WT controls (−39%, 
Student’s t-test, p < 0.01, n = 6). The data are expressed as mean ± SEM. *p < 0.05, **p < 0.01.
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In contrast to rats, MAO-B plays larger role in metabolizing DA in humans and some other species28,77,78. 
Moreover, MAO-A and MAO-B metabolize DA to different degrees in different brain areas79,80. Therefore, the dis-
crepancy between the aforementioned and our results can be due to species, gender, and/or regional differences 
as well as differences in experimental conditions (in vitro vs. in vivo, measurement of MAO activity vs. levels) and 
generation of PKO phenotype. Compensatory mechanisms could also contribute to the discrepancy. It has been 
well established that age accounts for different responses in parkin-null rodents and that parkin knockout models 
compensate better for the lack of parkin protein than parkin mutant models8. Moreover, activity of MAO-B in the 
striatum is decreased in mouse model of pre-symptomatic PD (~59% loss of DAergic axons) and returns to the 
control levels during symptomatic stage, whereas activity of MAO-A is unchanged in the pre-symptomatic PD 
model and augmented in the symptomatic PD13. Our data is consistent with these findings, suggesting that the 2 
month-old male PKO rats may represent a very early stage of PD, manifested by deficit in MAO-B function and 
increased ß-PEA levels, at which the nigrostriatal system still is able to compensate for consequences of parkin 
loss of function. Interestingly, REM sleep depravation in rats is associated with reduced activity of MAO-B and 
increased ß-PEA levels in the striatum81. Abnormal REM sleep is also associated with a risk for developing PD82 
and is a feature of early stages of the disease83. Furthermore, REM sleep depravation can be induced by activation 
of TAAR-1 receptor84.
ß-PEA is a ligand for the TAAR-1 receptor; therefore, the decrease in TAAR-1 levels observed in the PKO 
rats can be an adaptive response to the increase in ß-PEA levels, resulting in attenuated TAAR-1 signaling. The 
TAAR-1 receptor serves as a stabilizer of DAergic neurotransmission37. Thus, if necessary, TAAR-1 increases 
DAergic neurotransmission via phosphorylation-mediated interaction with the DAT and inhibits it via upreg-
ulation of D2S-mediated DA uptake and via downregulation of D2L-mediated postsynaptic signaling. As 
noted previously, a several fold increase in ß-PEA levels is needed to release DA via reversal of the DAT18,68,69,85. 
Consequently, the small alterations in trace aminergic system likely affected D2 receptor signaling only because 
it does not require high increases in ß-PEA to be regulated. Along these lines, it is plausible that the D2S levels 
increased while the levels of D2L decreased in the striatum of PKO rats in response to the decrease in TAAR-1 
levels, in order to normalize DAergic neurotransmission. The D2L receptor levels may have decreased also in 
response to constitutively increased ß-PEA levels as ß-PEA was reported to exert a direct stimulating action on 
postsynaptic DA receptors42. Of note, the studies in young PKO mice did not detect changes in total D2 receptor 
levels65,86 or binding for D2/D3 receptors87. These results agree with our finding of unchanged immunoreactivity 
of D2(S + L).
Neither the decrease in D2L levels nor the decrease in the TAAR-1 levels was accompanied by a similar 
decrease in the gene expression. Increased expression of DRD2 gene together with decreased levels of D2L pro-
tein may reflect impaired translation of DRD2 mRNA. Alternatively, as changes were detected in the glycosylated 
forms of D2L and TAAR-1, parkin deficit may trigger changes in posttranslational glycosylation of both recep-
tors in the Golgi apparatus where parkin localizes88. As aforementioned, mRNA translation process in parkin 
knockouts can be potentially decreased; however, not due to altered TDP-43 levels. TDP-43 acts as a repres-
sor of local translation in dendrites and synapses89,90 and, therefore, an increase and not a decrease in its levels 
would result in decreased translation. On the other hand, a mutant TDP-43 protein inhibits protein transport 
between the endoplasmic reticulum and Golgi apparatus in neuronal cells91, suggesting that a deficit in TDP-
43 may result in decreased levels of glycosylated D2L and TAAR-1. The identity of the TDP-43-positive 70 kDa 
band observed in WT and PKO rats, as well as the identity of the ~60 kDa band, detected in WT mice52,59, remains 
to be determined. Our finding is in contrast to the finding of Hebron and colleagues, who found that PKO mice 
have increased levels of TDP-43 (total and phosphorylated) compared to controls51, supporting the notion of 
species differences between parkin knockout models.
The alterations in ß-PEA, TAAR-1 and D2L receptor levels did not significantly affect basal locomotor activity 
of the PKO rats. The finding of normal basal locomotion in drug-naïve 2 month-old PKO rats is in agreement 
with a previous study in 4–8 month old PKO rats9 and young adult PKO mice62, and suggests normal DAergic 
neurotransmission in the striatum as well as in the nucleus accumbens, the main brain area mediating horizontal 
locomotor activity in parkin-deficient rodents. Interestingly, we found a significant decrease in small stereotypic 
movements (e.g. scratching, grooming) in the PKO rats compared to their WT counterparts, suggesting some 
dysregulation of the dorsal striatum (e.g. imbalanced D2 and D1 receptors) and cerebellum, two of the brain 
regions mediating these movements92,93. In the study of Dave and colleagues, PKO rats at 4, 6, and 8 months of 
age did not show any impairment in motor behaviors, including basal locomotion and stereotypic behaviors9. 
Thus, by the 4th month of age, PKO rats apparently undergo adaptive changes to compensate for these small motor 
impairments.
Amphetamine-induced DA release, an index of newly synthesized cytoplasmic DA, triggers locomotor 
activation in rodents. Decreased locomotor response to 2 mg/kg methamphetamine in the PKO rats as com-
pared to WT controls supports our hypothesis of smaller cytoplasmic DA pool in the knockouts. Attenuated 
responses to amphetamines were also noted in PKO mice. Thus, 1–5 mg/kg amphetamine elicited decreased 
locomotor response in 6 month-old PKO mice19 whereas 0.3 mg/kg methamphetamine elicited decreased loco-
motor response in 12 month-old PKO mice64. Another study showed no difference in locomotor response in 
3-month-old knockout mice compared to controls after treatment with 4 mg/kg of amphetamine57. Although 
these results are somewhat inconsistent, they suggest that the absence of parkin plays a role in evoked DA neu-
rotransmission via decreasing cytoplasmic DA pool. Similarly to PKO rodents, TAAR1 KO mice show normal 
locomotion at basal conditions but when challenged by amphetamine (2.5 mg/kg), they are hyperactive. This 
sensitivity has been shown to be due to an elevated spontaneous firing rate of DAergic neurons in the ventral 
tegmental area94. D2L receptor knockout mice display increased basal locomotor activity95. Thus, a decreased 
locomotor response to methamphetamine in the PKO rats may be due to altered activity of the basal ganglia.
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As opposed to conditional knockout, compensatory mechanisms occur during traditional transgenesis and, 
therefore, may be responsible, at least in part, for the lack of major dysregulation, or neurodegeneration, of 
DAergic system in PKO rodents. Alternatively, the knockout of Park2 gene does not recapitulate any PD-related 
phenotype. The PKO rodents; however, display some DAergic system impairments, particularly after exposure to 
stressors such as methamphetamine, which can oxidatively damage striatal proteins, including parkin96. Chronic 
methamphetamine users have been shown to be at risk for developing PD97,98; therefore, our data may be of rel-
evance to this finding. We present some neuronal adaptations that took place in the striatum of male PKO rats 
until the age of 2 months. It remains to be determined whether these rats represent an early model of PD with the 
nigrostriatal DA system still being able to compensate for parkin loss of function under non-stressful conditions. 
In addition, we present species differences in striatal responses to Park2 knockout that may be important for 
individualized treatment of PD patients.
Methods
Animals. The study was conducted on male 2 month-old Long Evans PKO rats (SAGE Labs, Missouri, MO) 
and age-matched male WT Long Evans rats (Harlan, Indianapolis, IN) weighing between 250–350 g. Upon 
arrival, the animals were maintained under standard environmental conditions in the institutional animal facil-
ities in a temperature and humidity controlled room, under a 12 h light/dark cycle with ad libitum access to food 
and water. Animals were weighted every day until the day of sacrifice (~PND63). All animal procedures were 
approved by the Institutional Animal Care and Use committee at Wayne State University and methods were car-
ried out in accordance with the approved guidelines (A 05–07–13). The description of animal procedures meet 
the ARRIVE recommended guidelines described by the National Centre for the Replacement, Refinement and 
Reduction of Animals in Research.
Tissue collection. PKO and WT Long Evans rat littermates were sacrificed for tissue harvest on the same 
day using decapitation. Whole striata and cerebella were dissected out, immediately frozen on dry ice, and stored 
at −80 °C until assayed.
High performance liquid chromatography. Striatal brain samples were prepared as previously 
described99. The tissue was sonicated in 0.5 mL of cold 0.3 M perchloric acid for 20–30 seconds (with 20% power) 
and centrifuged at 12, 000 × g for 30 min at 4 °C. The supernatant was collected with great caution (to avoid pel-
let) in 200 μL high performance liquid chromatography (HPLC) tube. The pellet was re-suspended in 1 M NaOH 
overnight at 4 °C and protein concentrations were determined using BCA Assay Kit (Thermo Fischer, Waltham, 
MA). To measure neurotransmitters and their metabolites, 20 or 100 µL of the supernatant was injected into the 
MDTM mobile phase (Thermo Scientific), at a flow rate of 0.5 mL/min. The samples were separated using C- 
18 reverse-phase column (150 × 3.2, 3 µM particle size, Thermo Scientific). The amount of DA, 5-HT and their 
metabolites: DOPAC, HVA, 3-MT and 5-HIAA were then analyzed based on electrochemical detection and the 
final values were presented as ng/μg protein.
Liquid chromatography coupled with tandem mass spectrometry assay of ß-phenylethylamine 
in rat brain tissue. The concentrations of ß-PEA in rat brain tissue samples were determined by a validated 
high-performance liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) method, as 
described below. Frozen brain tissue samples (weight ranging from 25 to 55 mg) were thawed on ice and homog-
enized in 10 volumes of ice-cold distilled water by using a Precellys 24 homogenizer (Bertin Technologies, 
Rockville, MD). The homogenate was transferred to a new Eppendorf tube and 3 volumes of ice-cold methanol 
were added. The mixture was vortex-mixed for 1 min, and centrifuged at 4 °C, 14,000 rpm, for 20 min. The super-
natant was transferred into a new tube and dried under vacuum at 10 °C using a Labconco refrigerated CentriVap 
concentrator (Kansas city, MO, USA). The residue was reconstituted in 47.5 µL mobile phase consisting of 0.1% 
formic acid in water and 0.1% formic acid in acetonitrile (98:2, v/v), to which 2.5 µL of the stable isotope-labeled 
internal standard, 2-phenyl-d5-ethylamine (d5-PEA), was added. The reconstitution solution was centrifuged 
at 4 °C, 14,000 RPM, for 5 min. Five microliter of the supernatant was subjected to LC-MS/MS analysis using a 
SHIMADZU (Kyoto, Japan) Nexera ultra high performance liquid chromatography system coupled with an AB 
SCIEX (Foster City, CA) QTRAP 6500 mass spectrometer.
Chromatographic separation was achieved on a Synergy polar-RP column (2 × 100 mm, 4 µm, 80 Å) 
(Phenomenex, Torrance, CA, USA) at 35 °C with a gradient mobile phase A (0.1% formic acid in double deion-
ized water) and B (0.1% formic acid in acetonitrile), at a flow rate of 0.3 mL/min. The optimized gradient pro-
gram (shown as time, mobile phase B) was as follows: 0–0.5 min, 0 to 2%; 0.5–1.5 min, 2% to 20%; 1.5–5 min, 
20% to 65%; 5–6.5 min, 65%; 6.5–7 min, 65% to 100%; 7–8.5 min, 100%; 8.5–8.7 min, 0%; and 8.7–12 min, 0%. 
The autosampler was set at 4 °C. The column effluent was monitored using the QTRAP 6500 mass spectrometer 
equipped with electrospray ionization source. The optimal MS conditions were obtained by direct infusion of the 
standard solution of ß-PEA and d5-PEA into the ion source. ß-PEA and d5-PEA were monitored under positive 
ionization mode at the MS transitions (m/z) of 122.0 > 105.0 and 127.0 > 110.0, respectively. The Turbo ion-spray 
voltage was 5500 V and the temperature was set at 475 °C. Collision gas was optimized at medium level, and cur-
tain gas was set at 30 psi with both ion source gas 1 and 2 at 50 psi. The declustering potential was set at 21 and 
25 V for ß-PEA and d5-PEA, respectively. The collision energy was 16 and 17 V for PEA and d5-PEA, respectively. 
The calibration curve of PEA was constructed at the concentration range of 0.2 to 100 nM. Intra- and inter-day 
precision and accuracy of the calibrators and quality control samples were within the generally acceptable bioan-
alytical criteria (<15%).
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SDS-PAGE and western blotting.  Tissue lysates and synaptosomal fractions (synaptosomal, mem-
brane, and vesicular fractions) were prepared from striatal and cerebellar brain samples by differential cen-
trifugation as previously described (Liu et al.100). Tissue pieces were homogenized in ice-cold RIPA buffer or 
in 0.5 mL 0.32 M sucrose solution containing protease inhibitor cocktail and centrifuged at 10,000 × g for 15 
min or at 800 × g for 24 min, respectively, at 4 °C. The supernatant form the low-speed centrifugation was then 
centrifuged again at 22,000 × g for 17 min at 4 °C, and the pellet dissolved in 150 µL ice-cold distilled water was 
retained as synaptosomal fraction. Part of the synaptosomal fraction was further centrifuged at 22,000 × g for 
17 min at 4 °C and the supernatant was retained as cytosolic fraction while the re-suspended pellet dissolved in 
ice-cold distilled water was retained as a membrane fraction. Sample protein concentrations were determined 
using BCA Assay Kit (Thermo Fischer). Striatal and cerebellar samples were diluted to even protein concentra-
tions in LDS sample buffer (Thermo Fischer) containing 5% ß-mercaptoethanol (Thermo Fischer). The samples 
were subsequently heated at 70 °C for 10 min, loaded onto sodium dodecyl sulfate-polyacrylamide gel (4–12% 
SDS-PAGE) (20–30 μg of protein per lane) and run at a constant voltage of 100 V for 60 min. Proteins were trans-
ferred onto methanol-activated PVDF membranes at 0.4 A for 60 min. Transfer efficiency and protein loading was 
asessed using Ponceau S dye (Sigma-Aldrich, St. Louis, MO). The membranes were then blocked for 60 min at 
room temperature in 5% non-fat dry milk dissolved in TBST (50 mM Tris-HCl pH 7.6, 150 mM NaCl, 0.05% 
Triton X-100). Membranes were then incubated overnight at 4 °C in one of the following primary antibodies 
diluted in the blocking buffer; anti-VMAT2 (1:3000, NB110-68123, Novus Biologicals, Littleton, CO), anti-DAT 
(1:500, SC1433, Santa Cruz Biotechnology, Dallas, TX), anti-parkin (1:1000, mouse 4211 S or rabbit 2132, Cell 
Signaling Technology, Danvers, MA), anti-TH (1:1000, 2043879, EMD Millipore, Billerica, MA,), anti-β-actin 
(1:2000, 3700, Cell Signaling Technology), anti-TAAR-1 (1:1000, sc398096, Santa Cruz Biotechnology), 
anti-TDP-43 (1:1000, 1078-2-AP, Proteintech, Chicago, IL), anti-MAO-B (1:1000, M1946, Sigma-Aldrich), anti 
D2L (1:1000, AB1792P, EDM Millipore), anti D2(S+L) (1:1000, AB1558, EDM Milliore) antibody, or antibody 
against 4-HNE-protein conjugates (1 µg/mL, R&D Systems, Minneapolis, MN). Membranes were washed 3 times 
for 5 minutes in TBST and incubated with appropriate secondary antibodies (anti-rabbit, anti-goat, or anti-mouse, 
1:10,000) for 60 min at room temperature. The membranes were washed again 3 times in TBST, incubated for 
2 min with SuperSignal West Pico chemiluminescence substrate (Thermo Scientific), and visualized using ECL 
detection and LAS4000 Bioimager (GE Healthcare, Piscataway, NJ). The levels of DA quinone-conjugated pro-
teins in striatal tissue were measured by redox-cycling staining according to the previously published protocol101. 
Briefly, the membrane with striatal proteins, separated by SDS-PAGE, were stained with Ponceau S (0.1% in 5% 
acetic acid), washed with water, and immersed in a solution of 0.24 mM nitro blue tetrazolium, 2 M potassium 
glycinate (pH 10.0) for 45 min in the dark. The reaction was stopped by immersing the membrane in the borate 
buffer (0.1 M, pH 10.0). DA quinone-bound bovine serum albumin (BSA) was used as a positive control. All 
immunoreactivities were quantified using ImageJ (National Institutes of Health, Bethesda, MD) and presented as 
a relative optical density units per mg proteins.
Immunohistochemistry. Fixed brain tissues were processed as previously described100. Citrate buffer anti-
gen retrieval (ThermoFisher, Waltham, MA, USA) was applied to all tissue sections. The sections were incu-
bated overnight at 4 °C with an anti-TAAR-1 antibody (sc398096, Santa Cruz Biotechnology) diluted 1:100 in the 
blocking buffer. The sections were then incubated for 2.5 h at room temperature with Alexa Fluor-488 conjugated 
secondary antibody (Invitrogen, Carlsbad, CA, USA). DRAQ5 (Invitrogen) was used to stain nuclei. The sec-
tions were then mounted using Fluoromount mounting medium (Southern Biotech, Birmingham, AL, USA). 
The immunostaining on each slice (3 sections per slice) was imaged using the Leica TCS SPE-II laser scanning 
confocal microscope (Leica, Wetzlar, Germany) and averaged per rat.
Monoamine oxidase activity assay. MAO-A and MAO-B activity in striatal mitochondria was analyzed 
based on fluorimetric technique using MAO Assay Kit (BioAssay systems) and Gen 5 All-in-one microplate 
reader software. Striatal mitochondria were isolated using commercially available Mitochondrial Isolation Kit 
for Tissue (Thermo Scientific, Rockford, IL). Striatal tissue were homogenized in 800 µL of bovine serum albu-
min (BSA)/Reagent A solution and dissolved in 800 µL Reagent C and centrifuged at 800 × g for 10 min at 4 °C. 
The supernatant was further centrifuged at 12,000 × g for 15 min at 4 °C and the mitochondrial pellet surface 
was washed with 500 µL wash buffer and dissolved with 1% digitonin, protease inhibitor in Reagent C. The 
re-suspended pellet was sonicated at 20% power, three times for 5 min, and centrifuged. The supernatants were 
used as sources for MAO. BCA assay was used for protein estimation. In order to determine MAO-A and MAO-B 
activities, samples were incubated with the substrate, p-tyramine, at 1 mM following establishing controls with 
0.5 µM MAO-A inhibitor, clorgyline or 0.5 µM MAO-B inhibitor, pargyline, respectively. Each MAO sample of 
45 µL was transferred into four separate wells of dark 96-well plate (BD Bioscience, Franklin Lakes, NJ), together 
with 5 µL of assay buffer, 5 µL of 10 µM clorgyline, or 5 µL of 10 µM pargyline. The solutions were then incubated 
for 10 min at room temperature for the inhibitors to block the reaction. To each well 47 µL assay buffer, 1 µL 
p-tyramine, 1 µL dye reagent, and 1 µL horse radish peroxidase (HRP) enzyme) was added and solutions were 
incubated for 20 min in the dark. The relative fluorescence intensity was measured at λext = 530/λEm = 585 nm), at 
room temperature (25 °C) for 60 minutes using Synergy H1 Hybrid reader (BioTek Highland Pak, VT).
Real-Time Polymerase Chain Reaction. The striata were disrupted with tissue grinder (Wheaton) and 
homogenized with a 20-gauge needle (BD). Total RNAs was extracted from the homogenates using RNeasy Mini 
Kit (Qiagen) in a presence of RNase-Free DNase Set (Qiagen) to remove genomic DNA. Total RNA concentra-
tion was measured using NanoDrop Lite Spectrophotometer (Thermo Scientific). One-step quantitative PCR 
was performed with Brilliant III ultra-fast SYBR® green qRT-PCR master mix kit (Agilent Technologies, Santa 
Clara, CA) using a Stratagene Mx3005 P system (Agilent Technologies). Each reaction started with 100 ng RNA 
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which was amplified by 40 cycles of 95 °C for 20 sec and 60 °C for 20 sec with an initial step of 55 °C for 10 min and 
95 °C for 3 min. Cycle threshold (Ct) values were determined by MxPro software (Agilent Technologies). Gene 
expressions were normalized by the expression of GAPDH and calculated using delta CT method. The primer 
sets (Qiagen) were the following: (i) TAAR1 (Cat. # QT00412069), MAOB (Cat. # QT00180887), DRD2 (Cat. # 
QT01081990), CHRNA7 (Cat. # QT00176561), and GAPDH (Cat. # QT00199633).
Drug treatment and motor activity measurement. Separate groups of PKO and WT rats were intra-
peritoneally (i.p.) injected with 2 mg/kg (free-base) of d-methamphetamine hydrochloride (Sigma-Aldrich, St. 
Louis, MO, USA) dissolved in sterile saline (0.9% NaCl). The gross motor activity of all the animals was assessed 
using the Opto-Varimex 4 AutoTrack open-field Plexiglass chamber (Columbus Instruments, Columbus, OH). 
At the beginning of each session, the animals were placed in the middle of the Plexiglass chamber, and their 
subsequent movement and position were recorded continuously. For each drug-naïve animal, motor activity was 
assessed during 30-min session. Activity of methamphetamine-treated rats was recorded for 100 min. Horizontal 
locomotor activity (distance travelled), and stereotypic movements (time spent) were calculated automatically 
from the raw beam-break data by the Opto-Varimex software.
Statistical analysis. The comparisons made in the study were pre-planned comparisons. Data sets were 
analyzed using two-tailed unpaired Student’s t-test or two-way ANOVA followed by Holm-Sidak’s post hoc test. 
Statistical analyses were performed using GraphPad Prism program (GraphPad Software, San Diego, CA) on the 
raw data with the exception of the western blotting data. The western blotting data are expressed as relative optical 
density units on each gel normalized to controls. This approach normalized differences across blots, allowing for 
standardization across the treatment groups. The data are presented as mean ± standard error (SEM). Statistical 
significance was set at p < 0.05.
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